Novartis has expanded its collaboration with Monte Rosa Therapeutics by securing exclusive rights to a new molecular glue degrader drug candidate and options for two additional programs, paying $120 million upfront. The deal could total up to $5.7 billion with milestone payments and royalties. Monte Rosa will conduct early discovery and clinical testing, while Novartis will take over development for selected programs. This partnership builds on an existing alliance focused on immune-mediated diseases, highlighting Novartis's commitment to targeted protein degradation as a therapeutic strategy. Monte Rosa aims to use the proceeds to advance multiple Phase 2 studies and its internal pipeline.